Reducción gradual de la medicación para el dolor en pacientes con síndrome de dolor espinal persistente tipo 2, tratados con estimulación de la médula espinal. (PIANISSIMO)
The primary objective of the study is to examine whether there is a difference in disability after 12 months of Spinal Cord Stimulation (SCS) in patients with Persistent Spinal Pain Syndrome Type 2 (PSPS T2) after receiving a standardized pain medication tapering protocol before SCS implantation, a personalized pain medication tapering protocol before SCS implantation, or no tapering protocol before SCS implantation. The secondary objective of the study is to examine whether there is a difference after 12 months of SCS in PSPS T2 patients after receiving a standardized pain medication tapering protocol before SCS implantation, a personalized pain medication tapering protocol before SCS implantation, or no tapering protocol before SCS implantation on pain intensity, health-related quality of life, participation, domains affected by substance use, anxiety and depression, medication use, psychological constructs, sleep, central sensitization, and healthcare expenditure.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Persistent Spinal Pain Syndrome Type II (PSPS T2) is a condition in which patients are suffering from persistent low back pain, despite previously performed surgical interventions. One way to help patients to alleviate their pain, is with Spinal Cord Stimulation (SCS). SCS is able to provide pain relief and a decrease in disability but also to decrease the amount of pain medication and more specifically opioid intake. Nevertheless, the number of patients that can eventually totally omit the use of opioids is rather limited.
In this trial, we will investigate the effect of a pain medication tapering program before starting the SCS trajectory as the new treatment strategy for patients implanted with SCS. This allows us to tackle the high burden of patients that are taking a lot of pain medication by proceeding towards a more logical treatment plan for a costly and debilitating condition.
A three-arm multicenter randomized controlled trial will be conducted to evaluate whether there is a difference in disability (primary outcome) after 12 months of SCS in PSPS T2 patients after receiving a standardized pain medication tapering protocol before SCS implantation, a personalized pain medication tapering protocol before SCS implantation, or no tapering protocol before SCS implantation. Two different pain medication tapering programs (standardized versus personalized tapering) will be evaluated in this project. Pain medication tapering will be provided to 130 patients during a hospital stay, compared to 65 patients who do not undergo pain medication tapering before SCS implantation. Besides disability as primary outcome measure, several secondary outcome measurements will be collected namely pain intensity, health-related quality of life, participation, domains affected by substance use, anxiety and depression, medication use, psychological constructs, sleep, central sensitization and health expenditure. Outcome measurements will be collected at baseline, and after 1 month, 3, 6 and 12 months of SCS.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Maarten Moens, Prof, Dr.
- Número de teléfono: +3224775514
- Correo electrónico: stimulusresearchgroup@gmail.com
Copia de seguridad de contactos de estudio
- Nombre: Lisa Goudman, Prof, Dr.
- Número de teléfono: +3224775514
- Correo electrónico: stimulusresearchgroup@gmail.com
Ubicaciones de estudio
-
-
-
Bruges, Bélgica
- Reclutamiento
- AZ Sint-Jan Brugge-Oostende
-
Contacto:
- Ophélie Vandemoortele, MD
- Correo electrónico: pijnkliniek@azsintjan.be
-
Jette, Bélgica, 1090
- Reclutamiento
- Universitair Ziekenhuis Brussel
-
Contacto:
- Maarten Moens, Prof, Dr.
- Número de teléfono: +3224775514
- Correo electrónico: stimulusresearchgroup@gmail.com
-
Kortrijk, Bélgica
- Reclutamiento
- AZ Groeninge
-
Contacto:
- Pieter-Jan Germonpre, MD
- Correo electrónico: anesthesie@azgroeninge.be
-
Lier, Bélgica, 2500
- Reclutamiento
- Heilig Hart Ziekenhuis Lier
-
Contacto:
- Sofie Denkens, Dr.
-
Roeselare, Bélgica, 8800
- Reclutamiento
- AZ Delta
-
Contacto:
- Bart Billet, Dr.
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients with PSPS T2, defined as patients suffering from neuropathic pain of radicular origin with pain in the lower back and/or leg(s), of an intensity of at least 4/10 on the Numeric Rating Scale, for a period of at least 6 months after a minimum of one anatomically successful spinal surgery and being refractory to conservative treatment (according to Belgian reimbursement rules from January 1st, 2018)
- Patients need to be scheduled for SCS to be eligible for participation in the study
- Currently taking opioids
- 18 years and older
- Speaking and reading Dutch or French
Exclusion Criteria:
- Being actively treated for cancer.
- Having a life expectancy below 6 months.
- Receiving intrathecal drug delivery.
- Patients with contraindications for Clonidine (e.g., known hypotension which requires medication) or for Buprenorphine/Naloxone (e.g., severe respiratory insufficiency, hepatic insufficiency).
- Epilepsy treated by Pregabalin.
- Currently using benzodiazepines at more than 40 mg diazepam-equivalents per day.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador activo: No pain medication tapering (usual care)
Usual care |
Usual care with respect to Spinal Cord Stimulation implantation |
|
Comparador activo: Standardized pain medication tapering
Standardized pain medication tapering |
A standardized pain medication tapering program before Spinal Cord Stimulator implantation. |
|
Comparador activo: Personalized pain medication tapering
Personalized pain medication tapering |
A personalized pain medication tapering program before Spinal Cord Stimulator implantation. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Disability
Periodo de tiempo: The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation
|
Disability, evaluated with the Oswestry Disability Index |
The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Pain intensity
Periodo de tiempo: The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
Pain intensity will be evaluated using a Visual Analogue Scale (100 mm). |
The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
|
Health-related Quality of Life
Periodo de tiempo: The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
Health-related quality of life will be assessed using the Euro Quality of Life with five dimensions and five levels. |
The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
|
Participation
Periodo de tiempo: The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
The Impact on Participation and Autonomy Questionnaire is used to evaluate participation. |
The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
|
Drug related patient characteristics and problems
Periodo de tiempo: The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
The Measurements in the Addictions for Triage and Evaluation is used assess drug related patient characteristics and problems. |
The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
|
Opioid craving
Periodo de tiempo: The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
Opioid craving will be assessed with the Visual Analogue Scale for Opioid Craving. |
The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
|
Risk for aberrant medication-related behaviour
Periodo de tiempo: The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
The Current Opioid Misuse Measure is used to evaluate the risk for aberrant medication-related behaviour. |
The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
|
Medication use
Periodo de tiempo: The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
The Medication Quantification Scale III is used to quantify pain medication use. |
The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
|
Healthcare utilization
Periodo de tiempo: The change in healthcare utilization starting from the baseline screening up to 12 months after the intervention.
|
Healthcare utilization is investigated by two means: expenditures associated with in-hospital care are inventoried using the hospital claims data whereas other costs are collected through self-reported (diaries and questionnaires). |
The change in healthcare utilization starting from the baseline screening up to 12 months after the intervention.
|
|
Anxiety and depression
Periodo de tiempo: The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
The Hospital Anxiety and Depression Scale is used to assess feelings of anxiety and depression. |
The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
|
General Self-Efficacy
Periodo de tiempo: The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
Perceived self-efficacy is evaluated using the General Self-Efficacy Scale. |
The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
|
Pain Catastrophizing
Periodo de tiempo: The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
With the Pain Catastrophizing Scale, catastrophizing thoughts or feelings accompanying the previously experienced pain are evaluated. |
The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
|
Coping
Periodo de tiempo: The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
The Multidimensional Pain Inventory is used to assess the participants coping strategy profile. |
The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
|
Sleep quality
Periodo de tiempo: The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
The Pittsburgh Sleep Quality Index is used to assess sleep quality. |
The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
|
Symptoms of Central Sensitization
Periodo de tiempo: The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
To assess symptoms associated with central sensitization, the Central Sensitization Inventory is used. |
The change between the baseline assessment and the evaluation 1 month, 3 months, 6 months, and 12 months after receiving Spinal Cord Stimulation.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
Otros números de identificación del estudio
- PIANISSIMO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .